Literature DB >> 17197144

Cancer vaccines in old age.

Claudia Gravekamp1.   

Abstract

The incidence of cancer has increased over the last decade, mainly due to an increase in the elderly population. Vaccine therapy for cancer is less toxic than chemotherapy or radiation and could be, therefore, especially effective in older, more frail cancer patients. However, it has been shown that older individuals do not respond to vaccine therapy as well as younger adults. This has been attributed to T cell unresponsiveness, a phenomenon also observed in cancer patients per se. This review summarizes the current knowledge of T cell unresponsiveness in cancer patients and elderly, the results of cancer vaccination in preclinical models and in clinical trials, and recent data of cancer vaccination at young and old age in preclinical models. Finally, experimental approaches will be proposed how to make cancer vaccines more effective at older age.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17197144      PMCID: PMC1978192          DOI: 10.1016/j.exger.2006.11.009

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  72 in total

1.  CD4+CD25+Foxp3+ T cells and CD4+CD25-Foxp3+ T cells in aged mice.

Authors:  Tomohisa Nishioka; Jun Shimizu; Ryuji Iida; Sayuri Yamazaki; Shimon Sakaguchi
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

2.  Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.

Authors:  Shari Pilon-Thomas; Wenbin Li; Jon J Briggs; Julie Djeu; James J Mulé; Adam I Riker
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

3.  A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.

Authors:  María M Barrio; Patricia T de Motta; Julio Kaplan; Erika M von Euw; Alicia I Bravo; Reinaldo D Chacón; José Mordoh
Journal:  J Immunother       Date:  2006 Jul-Aug       Impact factor: 4.456

Review 4.  Regulatory T cells, tumour immunity and immunotherapy.

Authors:  Weiping Zou
Journal:  Nat Rev Immunol       Date:  2006-04       Impact factor: 53.106

5.  Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Authors:  Margarita Salcedo; Nadège Bercovici; Rachel Taylor; Pierre Vereecken; Séverine Massicard; Dominique Duriau; Frédérique Vernel-Pauillac; Aurélie Boyer; Véronique Baron-Bodo; Eric Mallard; Jacques Bartholeyns; Béatrice Goxe; Nathalie Latour; Sophie Leroy; Didier Prigent; Philippe Martiat; François Sales; Marianne Laporte; Catherine Bruyns; Jean-Loup Romet-Lemonne; Jean-Pierre Abastado; Frédéric Lehmann; Thierry Velu
Journal:  Cancer Immunol Immunother       Date:  2005-09-27       Impact factor: 6.968

6.  Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide.

Authors:  Supriya Perambakam; Sigrun Hallmeyer; Samarth Reddy; Nadim Mahmud; Linda Bressler; Phillip DeChristopher; Delores Mahmud; Rafael Nunez; Jeffrey A Sosman; David J Peace
Journal:  Cancer Immunol Immunother       Date:  2005-11-10       Impact factor: 6.968

Review 7.  Immune suppression in the tumor microenvironment.

Authors:  Thomas F Gajewski; Yuru Meng; Helena Harlin
Journal:  J Immunother       Date:  2006 May-Jun       Impact factor: 4.456

8.  Recall immune memory: a new tool for generating late onset autoimmune myasthenia gravis.

Authors:  Sue Stacy; Anthony J Infante; Katherine A Wall; Keith Krolick; Ellen Kraig
Journal:  Mech Ageing Dev       Date:  2003 Aug-Sep       Impact factor: 5.432

9.  The phenotype of inflammatory macrophages is stimulus dependent: implications for the nature of the inflammatory response.

Authors:  Andrew D Cook; Emma L Braine; John A Hamilton
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

10.  Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.

Authors:  Helena Dzojic; Angelica Loskog; Thomas H Tötterman; Magnus Essand
Journal:  Prostate       Date:  2006-06-01       Impact factor: 4.104

View more
  4 in total

Review 1.  The importance of the age factor in cancer vaccination at older age.

Authors:  Claudia Gravekamp
Journal:  Cancer Immunol Immunother       Date:  2009-03-04       Impact factor: 6.968

2.  Aging, cancer, and cancer vaccines.

Authors:  Paolo Mazzola; Saba Radhi; Leonardo Mirandola; Giorgio Annoni; Marjorie Jenkins; Everardo Cobos; Maurizio Chiriva-Internati
Journal:  Immun Ageing       Date:  2012-04-17       Impact factor: 6.400

3.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Authors:  S H Kim; F Castro; D Gonzalez; P C Maciag; Y Paterson; C Gravekamp
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

4.  Immunity, ageing and cancer.

Authors:  Evelyna Derhovanessian; Rafael Solana; Anis Larbi; Graham Pawelec
Journal:  Immun Ageing       Date:  2008-09-24       Impact factor: 6.400

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.